HIV Diagnostics Market - Global Forecasts to 2030
商品番号 : SMB-74252
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年2月 |
| ページ数 | 274 |
| 図表数 | 382 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global HIV diagnostics market is projected to reach USD 5.31 Billion by 2030 from USD 3.25 Billion in 2025, at a CAGR of 10.3% during the forecast period.
世界の HIV診断市場は、予測期間中に 10.3% の CAGR で成長し、2025 年の 32 億 5,000 万米ドルから 2030 年までに 53 億 1,000 万米ドルに達すると予測されています。
The HIV diagnostics market is driven by several key factors, such as the rising prevalence of HIV/AIDS, the increasing number of blood transfusions and blood donations, advantages offered by POC diagnostic kits & instruments, and the growing focus on initiatives for HIV awareness. However, the high cost of nucleic acid testing, operational barriers, and the shortage of skilled laboratory technicians are expected to restrain the market growth to a certain extent.
HIV診断市場は、HIV/AIDS の蔓延率の上昇、輸血および献血の増加、POC 診断キットおよび機器の利点、HIV 啓発活動への注目の高まりなど、いくつかの重要な要因によって推進されています。ただし、核酸検査の高コスト、運用上の障壁、熟練した検査技師の不足により、市場の成長はある程度抑制されると予想されます。
Government-led health initiatives and widespread public awareness campaigns encouraging early HIV testing are key drivers of market growth. Additionally, continuous advancements in rapid testing technologies, along with the increasing availability and affordability of self-testing kits, are improving patient compliance and boosting adoption rates. The expansion of diagnostic laboratories, integration of artificial intelligence in diagnostics, and growing collaborations between healthcare organizations and private entities further contribute to market expansion.
However, certain challenges may hinder growth, including the high cost of diagnostic tests, limited access to healthcare in remote regions, and a shortage of skilled professionals to conduct and interpret tests. Regulatory hurdles and concerns regarding the accuracy and reliability of some testing methods also pose potential barriers.
Despite these challenges, the HIV diagnostics market is expected to experience steady growth, driven by increasing awareness, improved healthcare infrastructure, rising government funding for HIV screening programs, and the growing demand for fast, convenient, and highly accurate testing solutions. The increasing focus on early detection and timely intervention, combined with technological innovations in point-of-care testing, is likely to create significant opportunities for market players in the coming years. “The consumables segment accounted for the largest share of the market in 2024, by product.”
The HIV diagnostics market is classified by product type into consumables, instruments, and software & services. In 2024, the consumables segment dominated the market, driven by the recurring demand from laboratories and hospitals, the rising prevalence of HIV/AIDS, and government initiatives supporting the development of advanced consumables.
“The confirmatory tests segment accounted for the largest share of the market in 2024, by test type.”
By test type, the market is segmented into screening tests, confirmatory tests, and monitoring tests. The monitoring tests segment held the largest share in 2024 and is expected to grow at the highest CAGR. This growth is fueled by increasing awareness of HIV testing, a high volume of monitoring test samples, and the expansion of diagnostic laboratories specializing in HIV/AIDS testing. Additionally, advancements in monitoring test kits are further accelerating the segment’s expansion.
“Diagnostic Laboratories segment dominated the HIV diagnostics market in 2024, based on end user.”
The HIV diagnostics market is segmented by end users into diagnostic laboratories, hospitals, blood banks, home care settings, and others. In 2024, diagnostic laboratories accounted for the largest market share, driven by the increasing prevalence of HIV/AIDS, the expansion of diagnostic facilities, the rising demand for sample testing, and advancements in point-of-care (POC) technology.
The HIV diagnostics market is segmented into six key regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. In 2024, North America led the global market, driven by factors such as the rising prevalence of HIV/AIDS, advancements in point-of-care (POC) diagnostic instruments and test kits, growing awareness initiatives, and an increase in blood transfusions and donations. The presence of well-established healthcare infrastructure, significant investments in research and development, and supportive government policies further contributed to the region’s market dominance.
However, the Asia Pacific region is projected to experience the highest compound annual growth rate during the forecast period. This rapid expansion is fueled by the rising number of HIV cases, the increasing availability of advanced POC diagnostic products, and growing healthcare investments in emerging economies. Additionally, government-led initiatives promoting HIV awareness, improved healthcare accessibility, and a surge in global market players expanding their presence in the region are further accelerating market growth. The region’s increasing focus on early disease detection, combined with technological advancements and growing collaborations between public and private healthcare organizations, is expected to create significant opportunities for market expansion.
The break-up of the profile of primary participants in the HIV diagnostics market:
- By Company Type: Tier 1 – 55%, Tier 2 – 25%, and Tier 3 – 20%
- By Designation: M-level – 30%, D-level – 50%, and Others – 20%
- By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and Others-4%
The key players in this market are are Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Grifols, S.A. (Spain), Bio-Rad Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Hologic, Inc. (US), QIAGEN (Germany), Becton, Dickinson, and Company (US), Trinity Biotech (Ireland), OraSure Technologies (US), BioSynex SA (Chembio Diagnostics) (France), Wondfo (China), Getein Biotech Inc. (China), Meril Diagnostics (India), AccuBioTech (China), BioLytical Laboratories Inc. (Canada), BioLab Diagnostics (India), Alpine Biomedicals Pvt. Ltd (India), Molbio Diagnostics (India), Fortress Diagnostics (UK), AdvaCare Pharma (US), Adaltis s.r.l (Italy) among others.
Research Coverage:
This research report categorizes the HIV diagnostics market by device type (consumables, instruments, software & services ), by test type (screening tests, confirmatory tests, monitoring tests and other HIV diagnostic tests), by end user (diagnostic laboratories, blood banks, home care settings, hospitals and other endusers), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa and GCC Countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the HIV diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the HIV diagnostics market. Competitive analysis of upcoming startups in the HIV diagnostics market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall HIV diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Rising prevalence of HIV/AIDS, Increasing number of blood transfusions & blood donations, Advantages offered by POC diagnostic kits & instruments) opportunities (Growth opportunities in emerging economies), restraints (high cost of NATs), and challenges (lack of skilled workforce) influencing the growth of the HIV diagnostics market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the HIV diagnostics market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the HIV diagnostics market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the HIV diagnostics market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Grifols, S.A. (Spain).
Table of Contents
1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.3 MARKET SCOPE 28
1.3.1 MARKET SEGMENTATION 28
1.3.2 INCLUSIONS & EXCLUSIONS 29
1.3.3 YEARS CONSIDERED 30
1.3.4 CURRENCY CONSIDERED 30
1.4 STAKEHOLDERS 30
1.5 SUMMARY OF CHANGES 31
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH DATA 32
2.1.1 SECONDARY DATA 33
2.1.1.1 Key data from secondary sources 34
2.1.2 PRIMARY DATA 35
2.1.2.1 Primary sources 35
2.1.2.2 Key industry insights 36
2.1.2.3 Key data from primary sources 36
2.1.2.4 Breakdown of primary interviews 37
2.2 MARKET SIZE ESTIMATION 37
2.2.1 BOTTOM-UP APPROACH 38
2.2.1.1 Approach 1: Company revenue estimation approach 38
2.2.1.2 Approach 2: Presentations of companies and primary interviews 38
2.2.1.3 Growth forecast 39
2.2.1.4 CAGR projections 39
2.2.2 TOP-DOWN APPROACH 40
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 40
2.4 MARKET SHARE ASSUMPTIONS 41
2.5 STUDY ASSUMPTIONS 42
2.6 RESEARCH LIMITATIONS 42
2.7 RISK ASSESSMENT 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 47
4.1 HIV DIAGNOSTICS MARKET OVERVIEW 47
4.2 GEOGRAPHIC GROWTH OPPORTUNITIES 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
5.2.1 DRIVERS 52
5.2.1.1 Rising prevalence of HIV/AIDS 52
5.2.1.2 Increasing number of blood transfusions & blood donations 53
5.2.1.3 Advantages offered by POC diagnostic kits & instruments 53
5.2.1.4 Increasing initiatives for HIV awareness campaigns 54
5.2.2 RESTRAINTS 56
5.2.2.1 High cost of NATs 56
5.2.3 OPPORTUNITIES 56
5.2.3.1 High growth potential of emerging economies 56
5.2.3.2 Trend of self-testing and growing preference for at-
home diagnostic kits 57
5.2.4 CHALLENGES 57
5.2.4.1 Operational barriers and shortage of skilled laboratory technicians 57
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 58
5.4 PRICING ANALYSIS 58
5.4.1 AVERAGE SELLING PRICE OF HIV DIAGNOSTIC PRODUCTS,
BY KEY PLAYER, 2023 59
5.4.2 AVERAGE SELLING PRICE TREND, BY TEST TYPE, 2021−2023 59
5.4.3 AVERAGE SELLING PRICE TREND OF HIV DIAGNOSTIC INSTRUMENTS,
BY REGION, 2021−2023 (USD) 60
5.5 VALUE CHAIN ANALYSIS 60
5.6 SUPPLY CHAIN ANALYSIS 62
5.7 ECOSYSTEM ANALYSIS 63
5.8 TECHNOLOGY ANALYSIS 64
5.8.1 KEY TECHNOLOGIES 64
5.8.1.1 ELISA 64
5.8.2 COMPLEMENTARY TECHNOLOGIES 64
5.8.2.1 Western blot tests 64
5.8.3 ADJACENT TECHNOLOGIES 64
5.8.3.1 PCR 64
5.9 INVESTMENT & FUNDING SCENARIO 65
5.10 PATENT ANALYSIS 66
5.11 TRADE ANALYSIS 68
5.11.1 IMPORT DATA FOR HS CODE 3822 68
5.11.2 EXPORT DATA FOR HS CODE 3822 68
5.12 KEY CONFERENCES & EVENTS, 2025–2026 69
5.13 CASE STUDY ANALYSIS 70
5.13.1 ROLE OF COMMUNITY-BASED ORGANIZATIONS (CBOS) IN SUPPORTING PEOPLE WITH HIV 70
5.13.2 MANAGING HIGH BLOOD PRESSURE AND BLOOD SUGAR IN HIV-POSITIVE PATIENTS 71
5.14 REGULATORY LANDSCAPE 72
5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
5.14.2 REGULATORY FRAMEWORK 73
5.14.2.1 North America 73
5.14.2.1.1 US 73
5.14.2.1.2 Canada 73
5.14.2.2 Europe 74
5.14.2.3 Asia Pacific 75
5.14.2.3.1 China 75
5.14.2.3.2 Japan 75
5.14.2.3.3 India 75
5.14.2.4 Latin America 76
5.14.2.4.1 Brazil 76
5.14.2.4.2 Mexico 76
5.14.2.5 Middle East 76
5.14.2.6 Africa 77
5.15 PORTER’S FIVE FORCES ANALYSIS 77
5.15.1 THREAT OF NEW ENTRANTS 78
5.15.2 THREAT OF SUBSTITUTES 78
5.15.3 BARGAINING POWER OF BUYERS 78
5.15.4 BARGAINING POWER OF SUPPLIERS 78
5.15.5 INTENSITY OF COMPETITIVE RIVALRY 79
5.16 KEY STAKEHOLDERS & BUYING CRITERIA 79
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 79
5.16.2 KEY BUYING CRITERIA, BY PRODUCT 80
5.17 IMPACT OF AI/GENERATIVE AI ON HIV DIAGNOSTICS MARKET 80
5.17.1 MARKET POTENTIAL OF AI IN HIV DIAGNOSTICS 80
5.17.2 AI USE CASES 81
5.17.3 COMPANY IMPLEMENTATION OF AI 82
5.17.4 FUTURE OF AI/GENERATIVE AI 83
6 HIV DIAGNOSTICS MARKET, BY TEST TYPE 84
6.1 INTRODUCTION 85
6.2 SCREENING TESTS 86
6.2.1 RAPID TESTS 88
6.2.1.1 Provision of quick test results and ability to diagnose HIV antibodies to fuel uptake 88
6.2.2 ELISA 90
6.2.2.1 Wide applications across infectious disease diagnostics to drive market 90
6.2.3 OTHER SCREENING TESTS 92
6.3 CONFIRMATORY TESTS 94
6.3.1 WESTERN BLOT TESTS 97
6.3.1.1 Gold standard testing for result validation to drive market 97
6.3.2 OTHER CONFIRMATORY TESTS 99
6.4 MONITORING TESTS 101
6.4.1 VIRAL LOAD TESTS 103
6.4.1.1 Accurate provision of quantitative data on HIV infections to boost demand 103
6.4.2 CD4 TESTS 105
6.4.2.1 Ability to number CD4 T lymphocyte cells to support market growth 105
6.5 OTHER HIV DIAGNOSTIC TESTS 107
7 HIV DIAGNOSTICS MARKET, BY PRODUCT 110
7.1 INTRODUCTION 111
7.1.1 CONSUMABLES 112
7.1.2 ASSAY KITS & REAGENTS 114
7.1.2.1 Recurrent purchase to fuel market 114
7.1.3 OTHER CONSUMABLES 117
7.2 INSTRUMENTS 119
7.2.1 RISING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 119
7.3 SOFTWARE & SERVICES 122
7.3.1 INCREASING DEMAND FOR VALUE-ADDED SERVICES & AUTOMATED SOFTWARE TO SUPPORT MARKET GROWTH 122
8 HIV DIAGNOSTICS MARKET, BY END USER 125
8.1 INTRODUCTION 126
8.2 DIAGNOSTIC LABORATORIES 126
8.2.1 HIGH VOLUME OF HIV TESTING SAMPLES TO PROPEL MARKET 126
8.3 HOSPITALS 129
8.3.1 INCREASING ADOPTION OF DIAGNOSTIC TOOLS AND FAVORABLE REIMBURSEMENTS TO DRIVE MARKET 129
8.4 BLOOD BANKS 131
8.4.1 RISING NUMBER OF BLOOD DONATIONS TO BOOST DEMAND 131
8.5 HOME CARE SETTINGS 133
8.5.1 INCREASING PREFERENCE FOR AT-HOME TESTING KITS TO SUPPORT MARKET GROWTH 133
8.6 OTHER END USERS 136
9 HIV DIAGNOSTICS MARKET, BY REGION 138
9.1 INTRODUCTION 139
9.2 NORTH AMERICA 139
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 140
9.2.2 US 144
9.2.2.1 High healthcare expenditure to drive market 144
9.2.3 CANADA 147
9.2.3.1 Increasing number of HIV infections and blood donations to drive market 147
9.3 EUROPE 149
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 153
9.3.2 GERMANY 153
9.3.2.1 Favorable government healthcare policies and reimbursements for HIV testing to drive market 153
9.3.3 UK 156
9.3.3.1 Rising government support for HIV awareness campaigns to support market growth 156
9.3.4 FRANCE 159
9.3.4.1 High prevalence of HIV/AIDS to boost demand 159
9.3.5 ITALY 162
9.3.5.1 Increasing number of blood donors to support market growth 162
9.3.6 SPAIN 164
9.3.6.1 Rising adoption of NAT technology to propel market 164
9.3.7 REST OF EUROPE 167
9.4 ASIA PACIFIC 170
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 171
9.4.2 CHINA 174
9.4.2.1 Rising incidence of infectious diseases & HIV to propel market 174
9.4.3 JAPAN 177
9.4.3.1 Growing adoption of advanced HIV screening technologies to drive market 177
9.4.4 INDIA 180
9.4.4.1 Government initiatives such as free HIV testing to drive market 180
9.4.5 REST OF ASIA PACIFIC 183
9.5 LATIN AMERICA 185
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 186
9.5.2 BRAZIL 189
9.5.2.1 Increasing uptake of technologically advanced blood screening tests to drive market 189
9.5.3 MEXICO 191
9.5.3.1 Rising establishment of blood banks to support market growth 191
9.5.4 REST OF LATIN AMERICA 194
9.6 MIDDLE EAST & AFRICA 197
9.6.1 RISING NUMBER OF HIV DIAGNOSTICS AND SURGICAL PROCEDURES TO FUEL MARKET 197
9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 200
9.7 GCC COUNTRIES 200
9.7.1 RISING FOCUS ON HIV TESTING AND IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 200
9.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 203
10 COMPETITIVE LANDSCAPE 204
10.1 OVERVIEW 204
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 204
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN
HIV DIAGNOSTICS MARKET 204
10.3 REVENUE ANALYSIS, 2021–2023 206
10.4 MARKET SHARE ANALYSIS, 2023 207
10.4.1 RANKING OF KEY MARKET PLAYERS 209
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 209
10.5.1 STARS 209
10.5.2 EMERGING LEADERS 209
10.5.3 PERVASIVE PLAYERS 210
10.5.4 PARTICIPANTS 210
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 211
10.5.5.1 Company footprint 211
10.5.5.2 Region footprint 212
10.5.5.3 Product footprint 213
10.5.5.4 End-user footprint 213
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 214
10.6.1 PROGRESSIVE COMPANIES 214
10.6.2 RESPONSIVE COMPANIES 214
10.6.3 DYNAMIC COMPANIES 214
10.6.4 STARTING BLOCKS 214
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 215
10.6.5.1 Detailed list of key startups/SME players 215
10.6.5.2 Competitive benchmarking of key startups/SMEs 216
10.7 COMPANY VALUATION & FINANCIAL METRICS 217
10.8 BRAND/PRODUCT COMPARISON 218
10.9 COMPETITIVE SCENARIO 218
10.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 218
10.9.2 PRODUCT LAUNCHES & APPROVALS 218
10.9.3 DEALS 220
10.9.4 EXPANSIONS 221
10.9.5 OTHER DEVELOPMENTS 221
11 COMPANY PROFILES 222
11.1 KEY PLAYERS 222
11.1.1 ABBOTT 222
11.1.1.1 Business overview 222
11.1.1.2 Products/Services offered 223
11.1.1.3 Recent developments 225
11.1.1.3.1 Deals 225
11.1.1.4 MnM view 225
11.1.1.4.1 Key strengths 225
11.1.1.4.2 Strategic choices 225
11.1.1.4.3 Weaknesses & competitive threats 226
11.1.2 SIEMENS HEALTHINEERS 227
11.1.2.1 Business overview 227
11.1.2.2 Products/Services offered 228
11.1.2.3 Recent developments 229
11.1.2.3.1 Product/Service launches & approvals 229
11.1.2.3.2 Deals 230
11.1.2.3.3 Other developments 230
11.1.2.4 MnM view 230
11.1.2.4.1 Key strengths 230
11.1.2.4.2 Strategic choices 230
11.1.2.4.3 Weaknesses & competitive threats 230
11.1.3 GRIFOLS, S.A. 231
11.1.3.1 Business overview 231
11.1.3.2 Products/Services offered 233
11.1.3.3 Recent developments 234
11.1.3.3.1 Deals 234
11.1.3.4 MnM view 234
11.1.3.4.1 Key strengths 234
11.1.3.4.2 Strategic choices 234
11.1.3.4.3 Weaknesses & competitive threats 234
11.1.4 DANAHER CORPORATION 235
11.1.4.1 Business overview 235
11.1.4.2 Products/Services offered 236
11.1.4.3 Recent developments 237
11.1.4.3.1 Product launches & approvals 237
11.1.4.3.2 Deals 238
11.1.4.3.3 Expansions 238
11.1.4.4 MnM view 238
11.1.4.4.1 Key strengths 238
11.1.4.4.2 Strategic choices 238
11.1.4.4.3 Weaknesses & competitive threats 239
11.1.5 THERMO FISHER SCIENTIFIC INC. 240
11.1.5.1 Business overview 240
11.1.5.2 Products/Services offered 241
11.1.5.3 Recent developments 242
11.1.5.3.1 Product/Service launches & approvals 242
11.1.5.3.2 Deals 243
11.1.5.4 MnM view 243
11.1.5.4.1 Key strengths 243
11.1.5.4.2 Strategic choices 244
11.1.5.4.3 Weaknesses & competitive threats 244
11.1.6 BIO-RAD LABORATORIES, INC. 245
11.1.6.1 Business overview 245
11.1.6.2 Products/Services offered 246
11.1.6.2.1 Deals 247
11.1.7 F. HOFFMANN-LA ROCHE LTD. 248
11.1.7.1 Business overview 248
11.1.7.2 Products/Services offered 249
11.1.7.3 Recent developments 250
11.1.7.3.1 Product launches & approvals 250
11.1.7.3.2 Deals 250
11.1.7.3.3 Expansions 251
11.2 OTHER PLAYERS 252
11.2.1 BIOMÉRIEUX 252
11.2.2 HOLOGIC, INC. 253
11.2.3 QIAGEN 254
11.2.4 BD 255
11.2.5 TRINITY BIOTECH 256
11.2.6 ORASURE TECHNOLOGIES, INC. 257
11.2.7 BIOSYNEX SA 258
11.2.8 WONDFO 259
11.2.9 GETEIN BIOTECH, INC. 260
11.2.10 MERIL LIFE SCIENCES PVT. LTD. 261
11.2.11 ACCUBIOTECH CO., LTD. 261
11.2.12 BIOLYTICAL LABORATORIES INC. 262
11.2.13 BIO LAB DIAGNOSTICS (I) PRIVATE LIMITED 262
11.2.14 ALPINE BIOMEDICALS PVT LTD. 263
11.2.15 MOLBIO DIAGNOSTICS PVT. LTD. 263
11.2.16 FORTRESS DIAGNOSTICS 264
11.2.17 ADVACARE PHARMA (ACCUQUIK) 265
11.2.18 ADALTIS S.R.L. 265
12 APPENDIX 266
12.1 DISCUSSION GUIDE 266
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 270
12.3 CUSTOMIZATION OPTIONS 272
12.4 RELATED REPORTS 272
12.5 AUTHOR DETAILS 273
LIST OF TABLES
TABLE 1 HIV DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS 29
TABLE 2 HIV DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS 43
TABLE 3 NUMBER OF PEOPLE LIVING WITH HIV VS. NEW HIV CASES, BY REGION (2023) 52
TABLE 4 AVERAGE SELLING PRICE OF HIV DIAGNOSTICS PRODUCTS, BY KEY PLAYER, 2023 59
TABLE 5 AVERAGE SELLING PRICE TREND, BY TEST TYPE, 2021−2023 59
TABLE 6 AVERAGE SELLING PRICE TREND OF HIV DIAGNOSTIC INSTRUMENTS,
BY REGION, 2021−2023 (USD) 60
TABLE 7 HIV DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 63
TABLE 8 HIV DIAGNOSTICS MARKET: INNOVATIONS & PATENT REGISTRATIONS, 2023–2024 67
TABLE 9 IMPORT DATA FOR HS CODE 9021, BY COUNTRY, 2019–2023 (USD MILLION) 68
TABLE 10 EXPORT DATA FOR HS CODE 9021, BY COUNTRY, 2019–2023 (USD MILLION) 68
TABLE 11 HIV DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2025–2026 69
TABLE 12 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 72
TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 72
TABLE 14 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 73
TABLE 15 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
TABLE 16 EUROPE: CLASSIFICATION OF DEVICES 74
TABLE 17 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 75
TABLE 18 HIV DIAGNOSTICS MARKET: PORTER’S FIVE FORCES 78
TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%) 79
TABLE 20 KEY BUYING CRITERIA FOR PRODUCTS, BY RANK 80
TABLE 21 COMPANY IMPLEMENTATION OF AI IN HIV DIAGNOSTICS MARKET 82
TABLE 22 HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 85
TABLE 23 US: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (MILLION TESTS) 85
TABLE 24 US: HIV DIAGNOSTICS MARKET, BY RAPID TEST TYPE,
2022–2030 (MILLION TESTS) 86
TABLE 25 US: HIV DIAGNOSTICS MARKET, BY CONFIRMATORY TEST TYPE,
2022–2030 (MILLION TESTS) 86
TABLE 26 HIV DIAGNOSTICS MARKET FOR SCREENING TESTS, BY TYPE,
2022–2030 (USD MILLION) 86
TABLE 27 SCREENING TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 87
TABLE 28 NORTH AMERICA: SCREENING TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 87
TABLE 29 EUROPE: SCREENING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 87
TABLE 30 ASIA PACIFIC: SCREENING TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 88
TABLE 31 LATIN AMERICA: SCREENING TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 88
TABLE 32 RAPID TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 89
TABLE 33 NORTH AMERICA: RAPID TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 89
TABLE 34 EUROPE: RAPID TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 89
TABLE 35 ASIA PACIFIC: RAPID TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 90
TABLE 36 LATIN AMERICA: RAPID TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 90
TABLE 37 ELISA MARKET, BY REGION, 2022–2030 (USD MILLION) 91
TABLE 38 NORTH AMERICA: ELISA MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 91
TABLE 39 EUROPE: ELISA MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 91
TABLE 40 ASIA PACIFIC: ELISA MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 92
TABLE 41 LATIN AMERICA: ELISA MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 92
TABLE 42 OTHER SCREENING TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 93
TABLE 43 NORTH AMERICA: OTHER SCREENING TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 93
TABLE 44 EUROPE: OTHER SCREENING TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 93
TABLE 45 ASIA PACIFIC: OTHER SCREENING TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 94
TABLE 46 LATIN AMERICA: OTHER SCREENING TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 94
TABLE 47 CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 95
TABLE 48 CONFIRMATORY TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 95
TABLE 49 NORTH AMERICA: CONFIRMATORY TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 95
TABLE 50 EUROPE: CONFIRMATORY TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 96
TABLE 51 ASIA PACIFIC: CONFIRMATORY TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 96
TABLE 52 LATIN AMERICA: CONFIRMATORY TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 96
TABLE 53 WESTERN BLOT TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 97
TABLE 54 NORTH AMERICA: WESTERN BLOT TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 97
TABLE 55 EUROPE: WESTERN BLOT TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 98
TABLE 56 ASIA PACIFIC: WESTERN BLOT TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 98
TABLE 57 LATIN AMERICA: WESTERN BLOT TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 98
TABLE 58 OTHER CONFIRMATORY TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 99
TABLE 59 NORTH AMERICA: OTHER CONFIRMATORY TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 99
TABLE 60 EUROPE: OTHER CONFIRMATORY TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 100
TABLE 61 ASIA PACIFIC: OTHER CONFIRMATORY TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 100
TABLE 62 LATIN AMERICA: OTHER CONFIRMATORY TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 100
TABLE 63 MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 101
TABLE 64 MONITORING TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 101
TABLE 65 NORTH AMERICA: MONITORING TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 102
TABLE 66 EUROPE: MONITORING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 102
TABLE 67 ASIA PACIFIC: MONITORING TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 102
TABLE 68 LATIN AMERICA: MONITORING TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 103
TABLE 69 VIRAL LOAD TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 103
TABLE 70 NORTH AMERICA: VIRAL LOAD TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 104
TABLE 71 EUROPE: VIRAL LOAD TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 104
TABLE 72 ASIA PACIFIC: VIRAL LOAD TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 104
TABLE 73 LATIN AMERICA: VIRAL LOAD TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 105
TABLE 74 CD4 TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 105
TABLE 75 NORTH AMERICA: CD4 TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 106
TABLE 76 EUROPE: CD4 TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 106
TABLE 77 ASIA PACIFIC: CD4 TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 106
TABLE 78 LATIN AMERICA: CD4 TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 107
TABLE 79 OTHER HIV DIAGNOSTIC TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 108
TABLE 80 NORTH AMERICA: OTHER HIV DIAGNOSTIC TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 108
TABLE 81 EUROPE: OTHER HIV DIAGNOSTIC TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 108
TABLE 82 ASIA PACIFIC: OTHER HIV DIAGNOSTIC TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 109
TABLE 83 LATIN AMERICA: OTHER HIV DIAGNOSTIC TESTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 109
TABLE 84 HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 111
TABLE 85 HIV DIAGNOSTICS MARKET FOR CONSUMABLES MARKET, BY TYPE,
2022–2030 (USD MILLION) 112
TABLE 86 HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION,
2022–2030 (USD MILLION) 112
TABLE 87 NORTH AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2022–2030 (USD MILLION) 113
TABLE 88 EUROPE: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY,
2022–2030 (USD MILLION) 113
TABLE 89 ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2022–2030 (USD MILLION) 113
TABLE 90 LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2022–2030 (USD MILLION) 114
TABLE 91 ASSAY KITS & REAGENTS OFFERED BY KEY PLAYERS 115
TABLE 92 ASSAY KITS & REAGENTS MARKET, BY REGION, 2022–2030 (USD MILLION) 115
TABLE 93 NORTH AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 116
TABLE 94 EUROPE: ASSAY KITS & REAGENTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 116
TABLE 95 ASIA PACIFIC: ASSAY KITS & REAGENTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 116
TABLE 96 LATIN AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 117
TABLE 97 OTHER CONSUMABLES MARKET, BY REGION, 2022–2030 (USD MILLION) 117
TABLE 98 NORTH AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 118
TABLE 99 EUROPE: OTHER CONSUMABLES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 118
TABLE 100 ASIA PACIFIC: OTHER CONSUMABLES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 118
TABLE 101 LATIN AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 119
TABLE 102 KEY INSTRUMENTS AVAILABLE IN HIV DIAGNOSTICS MARKET 120
TABLE 103 HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION,
2022–2030 (USD MILLION) 120
TABLE 104 NORTH AMERICA: HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION) 121
TABLE 105 EUROPE: HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY,
2022–2030 (USD MILLION) 121
TABLE 106 ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION) 121
TABLE 107 LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION) 122
TABLE 108 HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION,
2022–2030 (USD MILLION) 123
TABLE 109 NORTH AMERICA: HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES,
BY COUNTRY, 2022–2030 (USD MILLION) 123
TABLE 110 EUROPE: HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES,
BY COUNTRY, 2022–2030 (USD MILLION) 124
TABLE 111 ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES,
BY COUNTRY, 2022–2030 (USD MILLION) 124
TABLE 112 LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES,
BY COUNTRY, 2022–2030 (USD MILLION) 124
TABLE 113 HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 126
TABLE 114 DIAGNOSTIC LABORATORIES MARKET, BY REGION, 2022–2030 (USD MILLION) 127
TABLE 115 NORTH AMERICA: DIAGNOSTIC LABORATORIES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 127
TABLE 116 EUROPE: DIAGNOSTIC LABORATORIES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 128
TABLE 117 ASIA PACIFIC: DIAGNOSTIC LABORATORIES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 128
TABLE 118 LATIN AMERICA: DIAGNOSTIC LABORATORIES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 128
TABLE 119 HOSPITALS MARKET, BY REGION, 2022–2030 (USD MILLION) 129
TABLE 120 NORTH AMERICA: HOSPITALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 130
TABLE 121 EUROPE: HOSPITALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 130
TABLE 122 ASIA PACIFIC: HOSPITALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 130
TABLE 123 LATIN AMERICA: HOSPITALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 131
TABLE 124 BLOOD BANKS MARKET, BY REGION, 2022–2030 (USD MILLION) 132
TABLE 125 NORTH AMERICA: BLOOD BANKS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 132
TABLE 126 EUROPE: BLOOD BANKS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 132
TABLE 127 ASIA PACIFIC: BLOOD BANKS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 133
TABLE 128 LATIN AMERICA: BLOOD BANKS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 133
TABLE 129 HOME CARE SETTINGS MARKET, BY REGION, 2022–2030 (USD MILLION) 134
TABLE 130 NORTH AMERICA: HOME CARE SETTINGS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 134
TABLE 131 EUROPE: HOME CARE SETTINGS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 135
TABLE 132 ASIA PACIFIC: HOME CARE SETTINGS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 135
TABLE 133 LATIN AMERICA: HOME CARE SETTINGS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 135
TABLE 134 OTHER END USERS MARKET, BY REGION, 2022–2030 (USD MILLION) 136
TABLE 135 NORTH AMERICA: OTHER END USERS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 136
TABLE 136 EUROPE: OTHER END USERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 137
TABLE 137 ASIA PACIFIC: OTHER END USERS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 137
TABLE 138 LATIN AMERICA: OTHER END USERS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 137
TABLE 139 HIV DIAGNOSTICS MARKET, BY REGION, 2022–2030 (USD MILLION) 139
TABLE 140 NORTH AMERICA: HIV DIAGNOSTICS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 140
TABLE 141 NORTH AMERICA: HIV DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 141
TABLE 142 NORTH AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES,
BY TYPE, 2022–2030 (USD MILLION) 141
TABLE 143 NORTH AMERICA: HIV DIAGNOSTICS MARKET, BY TEST TYPE,
2022–2030 (USD MILLION) 141
TABLE 144 NORTH AMERICA: SCREENING TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 142
TABLE 145 NORTH AMERICA: CONFIRMATORY TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 142
TABLE 146 NORTH AMERICA: MONITORING TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 142
TABLE 147 NORTH AMERICA: HIV DIAGNOSTICS MARKET, BY END USER,
2022–2030 (USD MILLION) 143
TABLE 148 US: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 144
TABLE 149 US: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2022–2030 (USD MILLION) 145
TABLE 150 US: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 145
TABLE 151 US: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 145
TABLE 152 US: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 146
TABLE 153 US: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 146
TABLE 154 US: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 146
TABLE 155 CANADA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 147
TABLE 156 CANADA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2022–2030 (USD MILLION) 147
TABLE 157 CANADA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 148
TABLE 158 CANADA: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 148
TABLE 159 CANADA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 148
TABLE 160 CANADA: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 149
TABLE 161 CANADA: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 149
TABLE 162 EUROPE: HIV DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 150
TABLE 163 EUROPE: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 150
TABLE 164 EUROPE: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2022–2030 (USD MILLION) 151
TABLE 165 EUROPE: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 151
TABLE 166 EUROPE: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 151
TABLE 167 EUROPE: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 152
TABLE 168 EUROPE: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 152
TABLE 169 EUROPE: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 152
TABLE 170 GERMANY: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 154
TABLE 171 GERMANY: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2022–2030 (USD MILLION) 154
TABLE 172 GERMANY: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 154
TABLE 173 GERMANY: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 155
TABLE 174 GERMANY: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 155
TABLE 175 GERMANY: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 155
TABLE 176 GERMANY: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 156
TABLE 177 UK: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 157
TABLE 178 UK: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2022–2030 (USD MILLION) 157
TABLE 179 UK: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 157
TABLE 180 UK: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 158
TABLE 181 UK: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 158
TABLE 182 UK: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 158
TABLE 183 UK: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 159
TABLE 184 FRANCE: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 159
TABLE 185 FRANCE: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2022–2030 (USD MILLION) 160
TABLE 186 FRANCE: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 160
TABLE 187 FRANCE: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 160
TABLE 188 FRANCE: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 161
TABLE 189 FRANCE: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 161
TABLE 190 FRANCE: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 161
TABLE 191 ITALY: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 162
TABLE 192 ITALY: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2022–2030 (USD MILLION) 162
TABLE 193 ITALY: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 163
TABLE 194 ITALY: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 163
TABLE 195 ITALY: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 163
TABLE 196 ITALY: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 164
TABLE 197 ITALY: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 164
TABLE 198 SPAIN: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 165
TABLE 199 SPAIN: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2022–2030 (USD MILLION) 165
TABLE 200 SPAIN: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 165
TABLE 201 SPAIN: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 166
TABLE 202 SPAIN: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 166
TABLE 203 SPAIN: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 166
TABLE 204 SPAIN: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 167
TABLE 205 REST OF EUROPE: HIV DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 167
TABLE 206 REST OF EUROPE: HIV DIAGNOSTICS MARKET FOR CONSUMABLES,
BY TYPE, 2022–2030 (USD MILLION) 168
TABLE 207 REST OF EUROPE: HIV DIAGNOSTICS MARKET, BY TEST TYPE,
2022–2030 (USD MILLION) 168
TABLE 208 REST OF EUROPE: SCREENING TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 168
TABLE 209 REST OF EUROPE: CONFIRMATORY TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 169
TABLE 210 REST OF EUROPE: MONITORING TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 169
TABLE 211 REST OF EUROPE: HIV DIAGNOSTICS MARKET, BY END USER,
2022–2030 (USD MILLION) 169
TABLE 212 ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 171
TABLE 213 ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 171
TABLE 214 ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2022–2030 (USD MILLION) 172
TABLE 215 ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY TEST TYPE,
2022–2030 (USD MILLION) 172
TABLE 216 ASIA PACIFIC: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 172
TABLE 217 ASIA PACIFIC: CONFIRMATORY TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 173
TABLE 218 ASIA PACIFIC: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 173
TABLE 219 ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY END USER,
2022–2030 (USD MILLION) 173
TABLE 220 CHINA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 174
TABLE 221 CHINA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2022–2030 (USD MILLION) 175
TABLE 222 CHINA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 175
TABLE 223 CHINA: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 175
TABLE 224 CHINA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 176
TABLE 225 CHINA: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 176
TABLE 226 CHINA: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 176
TABLE 227 JAPAN: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 177
TABLE 228 JAPAN: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2022–2030 (USD MILLION) 178
TABLE 229 JAPAN: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 178
TABLE 230 JAPAN: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 178
TABLE 231 JAPAN: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 179
TABLE 232 JAPAN: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 179
TABLE 233 JAPAN: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 179
TABLE 234 INDIA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 180
TABLE 235 INDIA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2022–2030 (USD MILLION) 181
TABLE 236 INDIA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 181
TABLE 237 INDIA: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 181
TABLE 238 INDIA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 182
TABLE 239 INDIA: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 182
TABLE 240 INDIA: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 182
TABLE 241 REST OF ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 183
TABLE 242 REST OF ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 183
TABLE 243 REST OF ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY TEST TYPE,
2022–2030 (USD MILLION) 184
TABLE 244 REST OF ASIA PACIFIC: SCREENING TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 184
TABLE 245 REST OF ASIA PACIFIC: CONFIRMATORY TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 184
TABLE 246 REST OF ASIA PACIFIC: MONITORING TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 185
TABLE 247 REST OF ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY END USER,
2022–2030 (USD MILLION) 185
TABLE 248 LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 186
TABLE 249 LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 186
TABLE 250 LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2022–2030 (USD MILLION) 187
TABLE 251 LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY TEST TYPE,
2022–2030 (USD MILLION) 187
TABLE 252 LATIN AMERICA: SCREENING TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 187
TABLE 253 LATIN AMERICA: CONFIRMATORY TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 188
TABLE 254 LATIN AMERICA: MONITORING TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 188
TABLE 255 LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY END USER,
2022–2030 (USD MILLION) 188
TABLE 256 BRAZIL: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 189
TABLE 257 BRAZIL: HIV DIAGNOSTICS MARKET FOR CONSUMABLES,
BY TYPE, 2022–2030 (USD MILLION) 189
TABLE 258 BRAZIL: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 190
TABLE 259 BRAZIL: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 190
TABLE 260 BRAZIL: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 190
TABLE 261 BRAZIL: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 191
TABLE 262 BRAZIL HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 191
TABLE 263 MEXICO: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 192
TABLE 264 MEXICO: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2022–2030 (USD MILLION) 192
TABLE 265 MEXICO: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 192
TABLE 266 MEXICO: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 193
TABLE 267 MEXICO: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 193
TABLE 268 MEXICO: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 193
TABLE 269 MEXICO: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 194
TABLE 270 REST OF LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 194
TABLE 271 REST OF LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES,
BY TYPE, 2022–2030 (USD MILLION) 195
TABLE 272 REST OF LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY TEST TYPE,
2022–2030 (USD MILLION) 195
TABLE 273 REST OF LATIN AMERICA: SCREENING TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 195
TABLE 274 REST OF LATIN AMERICA: CONFIRMATORY TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 196
TABLE 275 REST OF LATIN AMERICA: MONITORING TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 196
TABLE 276 REST OF LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY END USER,
2022–2030 (USD MILLION) 196
TABLE 277 MIDDLE EAST & AFRICA: HIV DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 197
TABLE 278 MIDDLE EAST & AFRICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 198
TABLE 279 MIDDLE EAST & AFRICA: HIV DIAGNOSTICS MARKET, BY TEST TYPE,
2022–2030 (USD MILLION) 198
TABLE 280 MIDDLE EAST & AFRICA: SCREENING TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 198
TABLE 281 MIDDLE EAST & AFRICA: CONFIRMATORY TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 199
TABLE 282 MIDDLE EAST & AFRICA: MONITORING TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 199
TABLE 283 MIDDLE EAST & AFRICA: HIV DIAGNOSTICS MARKET, BY END USER,
2022–2030 (USD MILLION) 199
TABLE 284 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 200
TABLE 285 GCC COUNTRIES: HIV DIAGNOSTICS MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 201
TABLE 286 GCC COUNTRIES: HIV DIAGNOSTICS MARKET FOR CONSUMABLES,
BY TYPE, 2022–2030 (USD MILLION) 201
TABLE 287 GCC COUNTRIES: HIV DIAGNOSTICS MARKET, BY TEST TYPE,
2022–2030 (USD MILLION) 201
TABLE 288 GCC COUNTRIES: SCREENING TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 202
TABLE 289 GCC COUNTRIES: CONFIRMATORY TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 202
TABLE 290 GCC COUNTRIES: MONITORING TESTS MARKET, BY TYPE,
2022–2030 (USD MILLION) 202
TABLE 291 GCC COUNTRIES: HIV DIAGNOSTICS MARKET, BY END USER,
2022–2030 (USD MILLION) 203
TABLE 292 GCC COUNTRIES: MACROECONOMIC INDICATORS 203
TABLE 293 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN
HIV DIAGNOSTICS MARKET 204
TABLE 294 HIV DIAGNOSTICS MARKET: DEGREE OF COMPETITION 207
TABLE 295 HIV DIAGNOSTICS MARKET: REGION FOOTPRINT 212
TABLE 296 HIV DIAGNOSTICS MARKET: PRODUCT FOOTPRINT 213
TABLE 297 HIV DIAGNOSTICS MARKET: END-USER FOOTPRINT 213
TABLE 298 HIV DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 215
TABLE 299 HIV DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 216
TABLE 300 HIV DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–MARCH 2025 218
TABLE 301 HIV DIAGNOSTICS MARKET: DEALS, JANUARY 2021–MARCH 2025 220
TABLE 302 HIV DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021–MARCH 2025 221
TABLE 303 HIV DIAGNOSTICS MARKET: OTHER DEVELOPMENTS,
JANUARY 2021–MARCH 2025 221
TABLE 304 ABBOTT: COMPANY OVERVIEW 222
TABLE 305 ABBOTT: PRODUCTS/SERVICES OFFERED 223
TABLE 306 ABBOTT: DEALS, JANUARY 2021–JANUARY 2025 225
TABLE 307 SIEMENS HEALTHINEERS: COMPANY OVERVIEW 227
TABLE 308 GRIFOLS, S.A.: COMPANY OVERVIEW 231
TABLE 309 GRIFOLS, S.A.: PRODUCTS/SERVICES OFFERED 233
TABLE 310 GRIFOLS, S.A.: DEALS, JANUARY 2021– JANUARY 2025 234
TABLE 311 DANAHER: COMPANY OVERVIEW 235
TABLE 312 DANAHER: PRODUCTS/SERVICES OFFERED 236
TABLE 313 DANAHER: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JANUARY 2025 237
TABLE 314 DANAHER: DEALS, JANUARY 2021–JANUARY 2025 238
TABLE 315 DANAHER: EXPANSIONS, JANUARY 2021–JANUARY 2025 238
TABLE 316 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 240
TABLE 317 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 241
TABLE 318 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JANUARY 2025 242
TABLE 319 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021−JANUARY 2025 243
TABLE 320 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 245
TABLE 321 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 246
TABLE 322 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021– JANUARY 2025 247
TABLE 323 F. HOFFMANN-LA ROCHE LTD..: COMPANY OVERVIEW 248
TABLE 324 F. HOFFMANN-LA ROCHE LTD..: PRODUCTS/SERVICES OFFERED 249
TABLE 325 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JANUARY 2025 250
TABLE 326 F. HOFFMANN-LA ROCHE LTD..: DEALS, JANUARY 2021– JANUARY 2025 250
TABLE 327 F. HOFFMANN-LA ROCHE LTD..: EXPANSIONS, JANUARY 2021– JANUARY 2025 251
TABLE 328 BD: COMPANY OVERVIEW 255
TABLE 329 TRINITY BIOTECH: COMPANY OVERVIEW 256
TABLE 330 BIOSYNEX SA: COMPANY OVERVIEW 258
TABLE 331 GETEIN BIOTECH, INC.: COMPANY OVERVIEW 260
TABLE 332 ADALTIS S.R.L.: COMPANY OVERVIEW 265
LIST OF FIGURES
FIGURE 1 MARKETS & REGIONS COVERED 28
FIGURE 2 HIV DIAGNOSTICS MARKET: RESEARCH DESIGN 32
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 37
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 38
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 39
FIGURE 6 HIV DIAGNOSTICS MARKET: TOP-DOWN APPROACH 40
FIGURE 7 DATA TRIANGULATION METHODOLOGY 41
FIGURE 8 HIV DIAGNOSTICS MARKET: STUDY ASSUMPTIONS 42
FIGURE 9 HIV DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION) 44
FIGURE 10 HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2030 (USD MILLION) 45
FIGURE 11 HIV DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 45
FIGURE 12 HIV DIAGNOSTICS MARKET, BY REGION, 2025 VS. 2030 (USD MILLION) 46
FIGURE 13 INCREASING PREVALENCE OF HIV AND RISING BLOOD DONATIONS
TO PROPEL MARKET 47
FIGURE 14 HIV DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION) 47
FIGURE 15 HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2030 (USD MILLION) 48
FIGURE 16 HIV DIAGNOSTICS SCREENING TESTS MARKET, BY TYPE,
2025 VS. 2030 (USD MILLION) 48
FIGURE 17 HIV DIAGNOSTICS CONFIRMATORY TESTS MARKET, BY TYPE,
2025 VS. 2030 (USD MILLION) 49
FIGURE 18 HIV DIAGNOSTICS MONITORING TESTS MARKET, BY TYPE,
2025 VS. 2030 (USD MILLION) 49
FIGURE 19 HIV DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 50
FIGURE 20 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 50
FIGURE 21 HIV DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
FIGURE 22 NEW REVENUE POCKETS FOR PLAYERS IN HIV DIAGNOSTICS MARKET 58
FIGURE 23 HIV DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS 61
FIGURE 24 HIV DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 62
FIGURE 25 HIV DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 63
FIGURE 26 INVESTMENT & FUNDING SCENARIO, 2018–2025 65
FIGURE 27 HIV DIAGNOSTICS MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024 66
FIGURE 28 HIV DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 77
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 79
FIGURE 30 KEY BUYING CRITERIA, BY PRODUCT 80
FIGURE 31 MARKET POTENTIAL OF AI IN HIV DIAGNOSTICS 81
FIGURE 32 HIV DIAGNOSTICS MARKET SEGMENTATION, BY PRODUCT 111
FIGURE 33 NORTH AMERICA: HIV DIAGNOSTICS MARKET SNAPSHOT 143
FIGURE 34 ASIA PACIFIC: HIV DIAGNOSTICS MARKET SNAPSHOT 170
FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN HIV DIAGNOSTICS MARKET,
2021−2023 (USD MILLION) 206
FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HIV DIAGNOSTICS MARKET (2023) 207
FIGURE 37 RANKING OF KEY PLAYERS IN HIV DIAGNOSTICS MARKET, 2023 209
FIGURE 38 HIV DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 210
FIGURE 39 HIV DIAGNOSTICS MARKET: COMPANY FOOTPRINT 211
FIGURE 40 HIV DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2023 215
FIGURE 41 EV/EBITDA OF KEY VENDORS 217
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 217
FIGURE 43 HIV DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 218
FIGURE 44 ABBOTT: COMPANY SNAPSHOT (2023) 223
FIGURE 45 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2023) 228
FIGURE 46 GRIFOLS, S.A.: COMPANY SNAPSHOT (2023) 232
FIGURE 47 DANAHER: COMPANY SNAPSHOT (2023) 236
FIGURE 48 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 241
FIGURE 49 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023) 246
FIGURE 50 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023) 249
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- ご注文後2営業日以内
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
割引可能なレポートが多数ございます。価格・サンプルについてはお気軽にご相談ください。
最新調査レポート
- 尿失禁デバイス市場 – 2030年までの世界予測 2025-03-12
- 医療用加湿器市場 – 2029年までの世界予測 2025-03-11
- BOPETフィルム市場 – 2029年までの世界予測 2025-03-11
- 金ナノ粒子市場 – 2029年までの世界予測 2025-03-07
- 沈降シリカ市場 – 2030年までの世界予測 2025-03-07